James Sapirstein
2021 - MARIZYME
In 2021, James Sapirstein earned a total compensation of $203.1K as former Interim Chief Executive Officer at MARIZYME.
Compensation breakdown
| Option Awards | $113,102 |
|---|---|
| Salary | $90,000 |
| Total | $203,102 |
Sapirstein received $113.1K in option awards, accounting for 56% of the total pay in 2021.
Sapirstein also received $90K in salary.
Rankings
In 2021, James Sapirstein's compensation ranked 11,972nd out of 12,415 executives tracked by ExecPay. In other words, Sapirstein earned more than 3.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,972 out of 12,415 | 4th |
Division Manufacturing | 5,295 out of 5,505 | 4th |
Major group Chemicals And Allied Products | 2,308 out of 2,375 | 3rd |
Industry group Drugs | 2,044 out of 2,096 | 3rd |
Industry Pharmaceutical Preparations | 1,510 out of 1,546 | 2nd |
Source: SEC filing on November 10, 2022.
Sapirstein's colleagues
We found seven more compensation records of executives who worked with James Sapirstein at MARIZYME in 2021.
2021
Steven Brooks
MARIZYME
Chief Medical Officer
2021
Catherine Pachuk
MARIZYME
Chief Scientific Officer
2021
Amy Chandler
MARIZYME
Former Executive Vice President of Regulatory Affairs and Quality Management Systems
2021
Neil Campbell
MARIZYME
Chief Executive Officer
2021
Roger Schaller
MARIZYME
former Executive Vice President of Commercial Operations
2021
David Barthel
MARIZYME
Chief Executive Officer
2021
Vithalbhai Dhaduk
MARIZYME